Best Practice & Research Clinical Rheumatology
Volume 20, Issue 5 , Pages 865-878 , October 2006

New cytokine targets in inflammatory rheumatic diseases

  • Iain B. McInnes, FRCP PhD (Professor of Experimental Medicine and Rheumatology)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44 141 211 4688; Fax: +44 141 211 4878.

References 

  1. Taylor PC, Williams RO, Maini RN. Immunotherapy for rheumatoid arthritis. Current Opinion in Immunology. 2001;13:611–616
  2. Gu Y, Kuida K, Tsutsui H, et al. Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme. Science. 1997;275(5297):206–209
  3. Ghayur T, Banerjee S, Hugunin M, et al. Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature. 1997;386:619–623
  4. Torigoe K, Ushio S, Okura T, et al. Purification and characterization of the human interleukin-18 receptor. The Journal of Biological Chemistry. 1997;272:25737–25742
  5. Gracie JA, Robertson SE, McInnes IB. Interleukin-18. Journal of Leukocyte Biology. 2003;73(2):213–224
  6. Matsui K, Yoshimoto T, Tsutsui H, et al. Propionibacterium acnes treatment diminishes CD4+ NK1.1+ T cells but induces type I T cells in the liver by induction of IL-12 and IL-18 production from Kupffer cells. Journal of Immunology (Baltimore, Md.: 1950). 1997;159(1):97–106
  7. Stoll S, Jonuleit H, Schmitt E, et al. Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development. European Journal of Immunology. 1998;28(10):3231–3239
  8. Pizarro TT, Michie MH, Bentz M, et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. Journal of Immunology (Baltimore, Md.: 1950). 1999;162(11):6829–6835
  9. Prinz M, Hanisch UK. Murine microglial cells produce and respond to interleukin-18. Journal of Neurochemistry. 1999;72(5):2215–2218
  10. Conti B, Jahng JW, Tinti C, et al. Induction of interferon-gamma inducing factor in the adrenal cortex. The Journal of Biological Chemistry. 1997;272(4):2035–2037
  11. Stoll S, Muller G, Kurimoto M, et al. Production of IL-18 (IFN-gamma-inducing factor) messenger RNA and functional protein by murine keratinocytes. Journal of Immunology (Baltimore, Md.: 1950). 1997;159(1):298–302
  12. Dao T, Mehal W, Crispe IN. IL-18 augments perforin-dependent cytotoxicity of liver NK-T cells. Journal of Immunology (Baltimore, Md.: 1950). 1998;161:2217–2222
  13. Micallef MJ, Ohtsuki T, Kohno K, et al. Interferon-gamma-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-gamma production. European Journal of Immunology. 1996;26(7):1647–1651
  14. Okamura H, Tsutsi H, Komatsu T, et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature. 1995;378:88–91
  15. Gutzmer R, Langer K, Mommert S, et al. Human dendritic cells express the IL-18R and are chemoattracted to IL-18. Journal of Immunology (Baltimore, Md.: 1950). 2003;171(12):6363–6371
  16. Wittmann M, Purwar R, Hartmann C, et al. Human keratinocytes respond to interleukin-18: implication for the course of chronic inflammatory skin diseases. The Journal of Investigative Dermatology. 2005;124(6):1225–1233
  17. Rooney T, Murphy E, Benito M, et al. Synovial tissue interleukin-18 expression and the response to treatment in patients with inflammatory arthritis. Annals of the Rheumatic Diseases. 2004;63(11):1393–1398
  18. Wei XQ, Leung B, Arthur HM, et al. Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18. Journal of Immunology (Baltimore, Md.: 1950). 2001;166(1):517–521
  19. Plater-Zyberk C, Joosten LA, Helsen MM, et al. Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. The Journal of Clinical Investigation. 2001;108(12):1825–1832
  20. Nishimoto N, Kishimoto T. Inhibition of IL-6 for the treatment of inflammatory diseases. Current Opinion in Pharmacology. 2004;4:386–391
  21. Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Research. 2002;4(supplement 3):S233–S242
  22. Butler D, Maini RN, Feldmann M, Brennan FM. Blockade of TNFα with chimeric anti TNFα monoclonal antibody, cA2 reduces (IL-6 and IL-8) release in RA NMC cultures: a comparison with IL-1ra. European Cytokine Network. 1995;6:225–230
  23. Alonzi T, Fattori E, Lazzaro D, et al. Interleukin 6 is required for the development of collagen-induced arthritis. The Journal of Experimental Medicine. 1998;187(4):461–468
  24. Takagi N, Mihara M, Moriya Y, et al. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis and Rheumatism. 1998;41:2117–2121
  25. Choy EHS, Isenberg DA, Garrood T, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis and Rheumatism. 2002;46:3143–3150
  26. Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis and Rheumatism. 2004;50:1761–1769
  27. Morita Y, Yamamura M, Nishida K, et al. Expression of interleukin-12 in synovial tissue from patients with rheumatoid arthritis. Arthritis and Rheumatism. 1998;41:306–314
  28. Hunter C. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nature Reviews Immunology. 2005;5(7):521–531
  29. Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity. 2003;19(5):641–644
  30. Hess H, Gately M, Rude E, et al. High doses of interleukin-12 inhibit the development of joint disease in DBA/1 mice immunized with type II collagen in complete Freund's adjuvant. European Journal of Immunology. 1996;26:187–191
  31. Malfait AM, Butler DM, Presky DH, et al. Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis. Clinical and Experimental Immunology. 1998;111:377–383
  32. Joosten LA, Lubberts E, Helsen MM, van den Berg WB. Dual role of IL-12 in early and late stages of murine collagen type II arthritis. Journal of Immunology (Baltimore, Md.: 1950). 1997;159:4094–4102
  33. Finnegan A, Grusby M, Kaplan CD, et al. IL-4 and IL-12 regulate proteoglycan-induced arthritis through Stat-dependent mechanisms. Journal of Immunology (Baltimore, Md.: 1950). 2002;169:3345–3352
  34. Joosten LA, Heuvelmans-Jacobs M, Lubberts E, et al. Local interleukin-12 gene transfer promotes conversion of an acute arthritis to a chronic destructive arthritis. Arthritis and Rheumatism. 2002;46:1379–1389
  35. Kauffman CL, Aria N, Toichi E, et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. The Journal of Investigative Dermatology. 2004;123(6):1037–1044
  36. Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn's disease. The New England Journal of Medicine. 2004;351(20):2069–2079
  37. Aggarwal S, Ghilardi N, Xie MH, et al. Interleukin-23 promotes a distinct T cell activation state characterized by the production of interleukin-17. The Journal of Biological Chemistry. 2003;278:1910–1914
  38. Murphy CA, Langrish C, Chen Y, et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. The Journal of Experimental Medicine. 2003;198:1951–1957
  39. Larousserie F, Pflanz S, Coulomb-L'Hermine A, et al. Expression of IL-27 in human Th1-associated granulomatous diseases. The Journal of Pathology. 2004;202(2):164–171
  40. Villarino AV, Huang E, Hunter CA. Understanding the pro- and anti-inflammatory properties of IL-27. Journal of Immunology (Baltimore, Md.: 1950). 2004;173(2):715–720
  41. Goldberg R, Wildbaum G, Zohar Y, et al. Suppression of ongoing adjuvant-induced arthritis by neutralizing the function of the p28 subunit of IL-27. Journal of Immunology (Baltimore, Md.: 1950). 2004;173(2):1171–1178
  42. Fehinger TA, Cooper M, Caligiuri MA. Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine & Growth Factor Reviews. 2002;13:169–183
  43. Waldmann T. Targeting the interleukin-15 system in rheumatoid arthritis. Arthritis and Rheumatism. 2005;52(9):2585–2588
  44. Lodolce J, Burkitt P, Koka R, et al. Interleukin-15 and the regulation of lymphoid homeostasis. Molecular Immunology. 2002;39:537–544
  45. Kurowska M, Rudnicka W, Kontny E, et al. Fibroblast like synoviocytes from rheumatoid arthritis patients express functional IL-15 receptor complex: endogenous IL-15 in autocrine fashion enhances cell proliferation and expression of Bcl-xL and Bcl-2. Journal of Immunology (Baltimore, Md.: 1950). 2002;169:1760–1767
  46. Dubois S, Mariner J, Waldmann TA, Tagaya Y. IL-15Rα recycles and presents IL-15 in trans to neighboring cells. Immunity. 2002;17:537–547
  47. Becknell B, Caligiuri M. Interleukin-2, interleukin-15, and their roles in human natural killer cells. Advances in Immunology. 2005;86:209–239
  48. McInnes IB, Gracie JA. Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Current Opinion in Pharmacology. 2004;4(4):392–397
  49. Ruchatz H, Leung B, Wei XQ, et al. Soluble IL-15 receptor alpha-chain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen-induced immunopathology. Journal of Immunology (Baltimore, Md.: 1950). 1998;160(11):5654–5660
  50. Baslund B, Tvede N, Danneskiold-Samsoe B, et al. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis and Rheumatism. 2005;52(9):2686–2692
  51. McInnes IB, Martin R, Zimmerman-Gorska I, et al. Safety and efficacy of a human monoclonal antibody to IL-15 (AMG 714) in patients with rheumatoid arthritis (RA): results from a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism. 2004;[abstract]
  52. Chabaud M, Durand J, Buchs N, et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis and Rheumatism. 1999;42(5):963–970
  53. Hwang SY, Kim HY. Expression of IL-17 homologs and their receptors in the synovial cells of rheumatoid arthritis patients. Molecules and Cells. 2005;19(2):180–184
  54. Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity. 2004;21:467–476
  55. Firestein GS, Zvaifler N. How important are T cells in chronic rheumatoid synovitis?: II. T cell-independent mechanisms from beginning to end. Arthritis and Rheumatism. 2002;46(2):298–308
  56. Lubberts E, Koenders MI, van den Berg WB. The role of T cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Research and Therapy. 2005;7:29–37
  57. Kotake S, Udagawa N, Hakoda M, et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis and Rheumatism. 2001;44(5):1003–1012
  58. Lubberts E, Koenders MI, Oppers-Walgreen B, et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis and Rheumatism. 2004;50(2):650–659

PII: S1521-6942(06)00071-4

doi: 10.1016/j.berh.2006.05.011

Best Practice & Research Clinical Rheumatology
Volume 20, Issue 5 , Pages 865-878 , October 2006

Article Tools